Loading
IMPDH is the bottleneck enzyme for making guanine nucleotides; mycophenolate blocks it to hold back the donor T cells that cause graft-versus-host disease after stem cell transplantation, and the enzyme is over-expressed in fast-growing tumours. This dossier gathers the 0 products (0 approved), 0 trials, 0 pathways and 0 resistance routes in the corpus that involve it, with external identifiers so it can be joined to UniProt, ChEMBL, Open Targets and the rest of biology.
A tetrameric NAD-dependent dehydrogenase that oxidises IMP to XMP; lymphocytes rely on this de novo route because they lack an efficient guanine salvage pathway.
| Cancer | Prevalence | Measure | Note | Source |
|---|---|---|---|---|
| Prostate cancer | host% | Host enzyme in normal and malignant prostate; finasteride and dutasteride were tested for prevention, not as a tumour marker | cancer.gov |
Approximate, population-level figures; the measure column says what was counted. Ranges show the midpoint as a bar.
No product in the corpus is aimed at this target yet.
No trial in the corpus names this target or one of its products.
No recorded escape route names this target.
No pathway diagram carries this target as a node.
No companion diagnostic in the registry measures this target.
No model entry for this target yet; check the cancer entries on the models page.
No open questions recorded for this target yet. Suggest one.
Query for this target: (TITLE:"IMP dehydrogenase" OR ABSTRACT:"IMP dehydrogenase" OR TITLE:"IMPDH2" OR ABSTRACT:"IMPDH2") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about IMP dehydrogenase (IMPDH2), not a curated reading list.
The dossier as machine-readable JSON, at /api/v1/dossiers/impdh2.json: identifiers from HGNC, Ensembl, UniProt and ChEMBL, products with status, trials, pathways, hotspots, open questions and assays. The full entity record is in the open API at /api/v1/entities/impdh2.json. Licence CC BY-NC 4.0.